Health-related quality of life and hemoglobin levels in chronic kidney disease patients

Hospital of St Raphael, Yale University, New Haven, CT 06511, USA.
Clinical Journal of the American Society of Nephrology (Impact Factor: 5.25). 12/2008; 4(1):33-8. DOI: 10.2215/CJN.00630208
Source: PubMed

ABSTRACT The relationship between quality of life (QofL) and anemia has been the subject of recent debates; it has been suggested that the QofL changes associated with the treatment of anemia of chronic kidney disease (CKD) or ESRD patients should not be used in making decisions to treat anemia in CKD patients.
This study examines the relationship between Kidney Disease Quality of Life (KDQofL) questionnaire domains and hemoglobin (Hgb) levels in 1200 patients with stage 3, 4, and 5 CKD followed in seven centers. QofL measures were compared in a stepwise fashion for hemoglobin levels of <11, 11 to <12, 12 to <13, and > or =13. ANOVA was used to examine the relationship between QofL scores and Hgb level, age, CKD stage, and albumin level; a history of diabetes, congestive heart failure, or myocardial infarction; use of erythropoetic-stimulating agents (ESA); and the interaction of hemoglobin level and ESA.
The results demonstrate that with increasing Hgb levels there is a statistically significant increase in all four physical domains, the energy/vitality domain, and the physical composite score of the SF-36, and the general health score on the kidney disease component of the questionnaire. The most dramatic improvements in these various domains occurred between the <11 and the 11 to 12 group.
Higher Hgb levels are associated with improved QofL domains of the KDQofL questionnaire. These findings have implications for the care of CKD patients in terms of the initiation of and the Hgb target of ESA therapy.

Download full-text


Available from: Salim Mujais, Jul 06, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: th decade before the advent of dialysis and transplantation. Recently introduced enzyme replacement therapy for alpha-galactosidase deficiency is an exciting advance in the treatment of what has become a potentially treatable cause of chronic kidney disease (CKD). Even though Fabry disease is an X-linked disease, it is now appreciated that many female "carriers" become clinically affected, although generally at a later age than affected males. Major efforts are underway to understand the causes of progressive renal insuffi- ciency in Fabry disease and identify optimal adjunctive therapy (eg, antiproteinuric agents) to slow disease progression. Pedigree and population screening efforts need to be carefully considered. Nephrologists play a critical role in the diagnosis and management of Fabry disease and are the providers of dialysis and transplantation, as well as enzyme replace- ment therapy in patients identified too late in the course of the disease to prevent the development of end-stage renal disease (ESRD). Plasma alpha-Gal A activity is very low or undetectable in patients with the classic phenotype. The progressive accumulation of GL-3 and other glycosphingolipids, particularly in the vascular endothelium and smooth muscle cells, leads to multi-organ manifestations that can be lethal in the fourth or fifth decade. Patients with milder variant phenotypes have reduced, but detectable levels of plasma alpha-Gal A activity. 6-8
  • [Show abstract] [Hide abstract]
    ABSTRACT: We consider monitoring the quality of compressed video transmitted over a packet network from the perspective of a network service provider. Our focus is on no-reference methods, which assume that the original signal is not available for computing the quality estimate. We present three methods to estimate mean squared error (MSE) from the video bitstream. The first method uses only network-level measurements (like packet loss rate), the second extracts the spatio-temporal extent of the impact of the loss, and the third extracts sequence-specific information including spatio-temporal activity and the effects of error propagation. Simulation results show that the first method has the lowest complexity but the worst performance, while the third method performs best with manageable complexity.
    Signals, Systems and Computers, 2002. Conference Record of the Thirty-Sixth Asilomar Conference on; 12/2002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Quality of Life (QOL) in patients with End Stage Renal Disease (ESRD) is an important measure of dialysis adequacy. Health related QOL is an independent risk factor for mortality in ESRD. The Kidney Disease QOL questionnaire is a highly validated disease targeted instrument with global application. We sought to document QOL and the predictive factors in a cohort of patients with ESRD in Jamaica and Panama. Two hundred patients were recruited consecutively from November 2006 - November 2007. Seventy patients were from a tertiary hospital based outpatient dialysis centre, the University Hospital of the West Indies (UHWI), and 40 patients from a private centre, Diabetes Association Renal Unit (DARU) both in Kingston, Jamaica. Ninety patients were consecutively recruited from a tertiary hospital based outpatient dialysis centre in Panama City, Panama. The Kidney Disease Quality of Life - Short Form Questionnaire was administered. Each QOL domain was scored from 0 - 100 with higher scores representing better rating. Mean age was 50 +/- 4 years, with no difference between the cohorts. Panama, however, had significantly higher parameters than the Jamaican cohorts: mean haemoglobin (Hb) 12.4g/dL (p = 0.004), mean serum albumin 45g/dL (p = 0.03) and Urea Reduction Ratio (URR) 78% (p = 0.004). Diabetes Association Renal Unit recorded mean Hb 11.4 +/- 1.3g/dL, mean serum albumin 42.1 +/- 2.3g/dL and URR 72%. The University Hospital of the West Indies documented mean Hb 11.2 +/- 2.4g/dL, mean serum albumin 41 +/- 4.5g/dL and URR 68%. All three cohorts had good overall QOL scores when compared with the reference population. Patients from Panama had higher overall QOL scores than Jamaican patients (p = 0.02). By centre, UHWI had higher overall QOL scores than DARU (p = 0.04). Burden of Kidney Disease domain recorded the lowest overall scores (Reference Population 49, DARU 19.0 (p = 0.001), UHWI 24.0 (p = 0.002), Panama 32.9 (p = 0.03). Patient Satisfaction scores were also significantly reduced across all cohorts (Reference population 72, DARU 52, UHWI 54, Panama 58). The University Hospital of the West Indies had significantly decreased dialysis staff encouragement (p = 0.003). The Diabetes Association Renal Unit noted significant reductions in general health (p = 0.04), physical functioning (p = 0.001), physical role (p = 0.001) and emotional role (p = 0.005) domains. Panama had the lowest overall physical functioning (p = 0.01), pain (p = 0.01) and social support (p = 0.04) scores. In the Panamanian cohort, age< 65 years (p = 0.0004). Hb > 11.1 g/dL (p = 0.01), albumin > 40g/dL (p = 0.01), URR > 65% (p = 0.03), race (p = 0.04), at least high school educational attainment (p = 0.01) and household yearly salaries > US$5000 (p = 0.002) predicted good QOL scores. These accounted for 55% of the variance. In the Jamaican cohort, however, younger age (p = 0.02), race (p = 0.001), higher URR (p = 0.01) and higher serum haemoglobin (p = 0.001) predicted higher QOL scores, accounting for only 40% of the variance. By modality, haemodialysis patients had significantly higher haemoglobin (p = 0.003) and albumin (p = 0.002) levels and ultimately higher overall QOL scores (p = 0.01). Overall, QOL is good in patients with ESRD. Domains of highest concern include Burden of Kidney Disease and Patient Satisfaction. The role of spirituality, depression and nutritional markers (eg prealbumin) needs to be assessed. Quality of Life must therefore be routinely documented in ESRD patients and targeted interventions implemented.
    The West Indian medical journal 06/2009; 58(3):235-42. · 0.28 Impact Factor